PARP + Maintenance Bevacizumab in Ovarian Cancer

Expert report on survival data from pivotal trials with PARP inhibitors for BRCA-mut. Ovarian CancerПодробнее

Precision Medicine for Ovarian Cancer (2021)Подробнее

Maintenance Therapy in Ovarian Cancer: What You Should KnowПодробнее

Enhancing Personalized Medicine in Ovarian Cancer: Advances in PARP Inhibition and Novel ModalitiesПодробнее

Professor Gordon Jayson: treating ovarian cancer with anti-angiogenic agentsПодробнее

What is Maintenance therapy with Lynparza plus Avastin ? | OncoPowerПодробнее

3/26/2021: Upfront Treatment of Advanced Ovarian Cancer; Ay, Now the Plot ThickensПодробнее

Personalizing Advanced Ovarian Cancer Treatment With PARP Inhibitors and Novel ApproachesПодробнее

The effectiveness of bevacizumab (Avastin) and related trialsПодробнее

Olaparib Maintenance Retreatment in Epithelial Ovarian CancerПодробнее

Updates in Ovarian Cancer: Frontline MaintenanceПодробнее

Maintenance Therapy in Stage IIIc Ovarian CancerПодробнее

Is It Time to Change Upfront Chemotherapy for Ovarian Cancer?Подробнее

Maintenance Therapy in Ovarian CancerПодробнее

Maintenance Therapy Options for Ovarian CancerПодробнее

Implications of PAOLA-1 in Advanced Ovarian CancerПодробнее

Ovarian Cancer: Maintenance Following Frontline BevacizumabПодробнее

Expert Views on the Evolving Role of PARP Inhibitors in the Treatment of Ovarian CancerПодробнее

Barriers to Use of PARP Inhibitor Maintenance for Patients With Ovarian CancerПодробнее

Dr. Herzog on the FDA Approval of Olaparib/Bevacizumab as Frontline Maintenance in Ovarian CancerПодробнее